U.K. drugmaker McCallum gets FDA warning over data, testing issues

fda
U.K. drugmaker McCallum gets FDA warning over data, testing issues. (FDA)

McCallum, a U.K.-based drugmaker, was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

In the letter posted on the regulatory agency’s website, the FDA took McCallum to task when the company said in response to a July 2017 inspection that it was too small an enterprise and didn’t have the resources for a quality unit.

“Regardless of the size of your company, as a drug manufacturer, you must have a quality unit that is responsible for and authorized to perform certain operations,” the FDA wrote.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

McCallum, an over-the-counter manufacturing operation, was found to lack testing procedures, specifications and analytical data to support the release of its products. The company also didn’t have adequate written procedures for production and process control in place, as well as failing to prepare batch production and control records.

The agency recommended the company hire a CGMP consultant to fix the issues.

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.